Condition

Malignant Solid Tumor

ClinicalTrials.gov condition label

Clinical trials6

Recruiting1

Common interventions16

Lead sponsors shown5

Clinical trials

6 shown

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid TumorsNCT06171750 · 2024-01-19

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)NCT05103358 · 2022-03-10

Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CTNCT04168528 · 2019-11-05

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsNCT04083599 · 2019-09-17

ACTIVE_NOT_RECRUITING

A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-CisplatinNCT01606748 · 2012-08-01

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung CancerNCT00452413 · 2007-05-01

Common interventions

CisplatinDRUG2 GemcitabineDRUG2 5-FUDRUG1 68GaNOTA-Anti-MMR-VHH2DRUG1 CarboplatinDRUG1 CemiplimabDRUG1 enzastaurinDRUG1 erlotinibDRUG1 GEN1042BIOLOGICAL1 Nab paclitaxelDRUG1 nab-sirolimusDRUG1 NecitumumabBIOLOGICAL1 PaclitaxelDRUG1 PembrolizumabDRUG1 PemetrexedDRUG1 tolododekin alfaDRUG1

Leading sponsors

Eli Lilly and Company2 Aadi Bioscience, Inc.1 Ankyra Therapeutics, Inc1 Genmab1 Universitair Ziekenhuis Brussel1

Trial status mix

COMPLETED3

ACTIVE_NOT_RECRUITING1

RECRUITING1

TERMINATED1

Phase mix

PHASE25

PHASE14

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.